GenSight Biologics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSGTF research report →
About the company
GenSight Biologics S. A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration.
- CEO
- Laurence Rodriguez
- IPO
- 2018
- Employees
- 16
- HQ
- Paris, FR
Price Chart
- Market Cap
- $14.67M
- P/E
- -1.02
- P/S
- 13529.00
- P/B
- -0.63
- EV/EBITDA
- -2.13
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1168400.00%
- Net Margin
- -1203600.00%
- ROE
- 42.20%
- ROIC
- 1515.43%
- Revenue
- $999.63 · -99.93%
- Net Income
- $-12,031,491 · 14.07%
- EPS
- $-0.08 · 52.24%
- Op Income
- $-11,700,615
- FCF YoY
- 29.09%
- 52W High
- $0.48
- 52W Low
- $0.09
- 50D MA
- $0.17
- 200D MA
- $0.18
- Beta
- 0.64
- Avg Volume
- 6
Get TickerSpark's AI analysis on GSGTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GSGTF coverage
Recent articles, reports, and earnings notes.
No research on GSGTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GSGTF report →Similar companies
Peers in the same neighborhood.